The implications of high prices for cancer drugs on health care costs and patients' financial burdens are a growing concern. Patients with metastatic castrate-resistant prostate cancer (mCRPC) are ...

Targeted cancer therapies are an expanding field of effective therapeutic approaches. While previous chemotherapy agents indiscriminately killed rapidly proliferating cells, newer “precision medicine” ...

An expert on prostate cancer gives a brief overview of castrate-resistant prostate cancer. This is a synopsis of an Educated Patient Sound Bites series featuring Alicia Morgans, MD, MPH, of ...

The development of effective cancer therapeutics depends largely on availability of experimental models that reflect the biology and pharmacological susceptibility of the tumor type they represent.

According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime. In addition, about 1 in 44 men will die from the disease, ...